Larotrectinib

Overview

Larotrectinib is a selective inhibitor of the tropomyosin receptor kinases (TRKA, TRKB, and TRKC), indicated for the treatment of solid tumors with a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation. It is designed to treat adult and pediatric patients with NTRK fusion-positive tumors regardless of the tumor location.

Patent & exclusivity (US)

Per the FDA Orange Book (3 approved US products), the latest listed US patent on Larotrectinib expires 15 May 2037. Generic API sourcing typically opens up once these lapse.

Therapeutic areas